Psoriasis Clinical Trial
Official title:
Comparative Analysis of Small and Large Plaque Psoriasis
Psoriasis is a chronic, debilitating skin disorder with an estimated prevalence of 2%.
Psoriatic skin lesions start with initial pinhead-sized macules and then coalesce into
plaques of varying sizes. Despite the great strides in the studies for psoriasis, it is
still unclear why psoriatic skin lesions start with small macules and then spread
peripherally.
To study peripheral spreading of psoriasis, investigators plan to study small plaque
psoriasis in comparison to large plaque psoriasis in the Korean population. Large plaque
psoriasis is the most common form of psoriasis, seen in approximately 90% of all psoriasis
participants. Large psoriatic plaques are >5 cm in size and localize to the extensor aspects
of the elbows, knees, scalp, and genital area. On the other hand, small plaque psoriasis is
the common or typical form of psoriasis that occurs particularly in Korea and other Asian
countries. Korean small plaque psoriasis, even when chronic, remains <2 cm in size and is
widely distributed on the upper trunk and proximal extremities.
Investigators hypothesize that the expression of immune-related genes are different between
small and large plaque psoriasis. The study of a genetically homogeneous cohort,
characterized by the relatively high prevalence of small plaque psoriasis in the Korean
population, may filter out spurious signals while allowing for significant associations to
emerge from a relatively low number of participants.
By comparing small and large plaque psoriasis, it is expected this study could lead to new
understandings of the mechanisms involved in spreading of psoriatic plaques and provide new
insights into psoriasis development.
Psoriasis is a common chronic skin disorder with an estimated prevalence in populations of
approximately 2%. Psoriatic skin lesions start with initial pinhead-sized macules and then
coalesce into plaques of varying sizes in diameter from one to several centimeters.
Despite the great strides in the studies for psoriasis, it is still unclear why psoriatic
skin lesions start with small macules and then spread peripherally. The occurrence of
psoriasis is thought to be the pathological consequence of an exaggerated immune response as
activated T cells, monocytes, neutrophils, and dendritic cells produce inflammatory
cytokines that drive the additional recruitment of inflammatory cells, further elaboration
of proinflammatory mediators, and the proliferation of keratinocytes. However, pathogenetic
mechanism for peripheral spreading of psoriasis needs to be further elucidated.
To study peripheral spreading of psoriasis, investigators plan to study "small plaque
psoriasis" and compare it to "large plaque psoriasis" in the Korean population.
Psoriasis vulgaris, so-called "large plaque psoriasis", is the most common form of
psoriasis, seen in approximately 90% of all psoriasis patients. Red, scaly, symmetrically
distributed plaques are usually larger than 5 cm in diameter and characteristically
localized to the extensor aspects of the extremities, particularly the elbows and knees,
along with scalp, lower lumbosacral, buttocks, and genital involvement. Approximately 1/4 to
1/3 of large plaque psoriasis participants have involvement of over 5% of their body surface
area (BSA), and disease of this extent is frequently painful and physically and/or socially
debilitating to a degree comparable with other chronic medical conditions.
On the other hand, "small plaque psoriasis" is the common or typical form of psoriasis that
occurs in adults particularly in Korea and other Asian countries. Korean small plaque
psoriasis, even when chronic, remain <2 cm in size and widely distributed on upper trunk and
proximal extremities. Small plaque psoriasis is less severe than large plaque psoriasis, as
it usually responds to phototherapy and more potent therapies are rarely needed.
It is also noteworthy that there are well-known human leukocyte antigen (HLA) differences in
Caucasians in comparison with Asian participants with psoriasis, and a unique HLA haplotype
has been described in Korean participants with psoriasis. Furthermore, an allele of an
HLA-related gene, known as major histocompatibility complex I chain-related gene A, is known
as a susceptibility marker in Korean and Chinese participants with psoriasis, but not in
Spanish participants.
For a more comprehensive analysis of the difference between small and large plaque
psoriasis, investigators plan to compare these two different types of psoriasis only in the
Korean population. The study of a genetically homogeneous cohort, characterized by the
relatively high prevalence of small plaque psoriasis in the Korean population, may filter
out spurious signals while allowing for significant associations to emerge from a relatively
low number of participants. By comparing Korean psoriasis participants in two geographically
separated locations (Seoul, Korea vs. New York, NY, USA), it will also be interesting to
understand the interactions between genetics and the environment that are still not well
defined.
It is anticipated this study could lead to new understanding of the mechanisms involved in
the spreading of psoriatic plaques and provide new insight into psoriasis pathogenesis.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |